Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0OX1Y
|
||||
| Former ID |
DIB001267
|
||||
| Drug Name |
Ad5-ENVA-48
|
||||
| Synonyms |
Ad26-ENVA-01; Ad5-HVR48-ENVA-01; HIV vaccine (ad35 vector), IAVI/Crucell; Recombinant envelope adenovirus 5 vaccine (HIV infection), Crucell/Harvard Medical School; Adenovirus vector vaccine (HIV infection), IAVI/Crucell/BIDMC/Harvard; HIV vaccine (rAd26 vector), IAVI/Crucell/Beth Israel Deaconess Medical Center/Harvard; HIV vaccine (AdVac, PER.C6), Crucell/IAVI/BIDMC/Harvard
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | HIV-1 infection [ICD9: 001-139, 042; ICD10:B20-B24] | Phase 1 | [522346] | ||
| Company |
Crucell NV
|
||||
| Target and Pathway | |||||
| Target(s) | HIV env | Target Info | [522346] | ||
| References | |||||